Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL28092084 | 1.00 | — | — | |
| Lithium Ion SCHEMBL5676964 | 0.94 | ALDH1A1 (0.30) | ALDH1A1TSHR | |
| Lithium Ion SCHEMBL27531913 | 0.88 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| Lithium Ion SCHEMBL1248330 | 0.88 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| Lithium Ion SCHEMBL74921 | 0.88 | — | — | |
| SCHEMBL27502661 | 0.88 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| SCHEMBL242908 | 0.88 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| SCHEMBL27287 | 0.88 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| Lithium Ion SCHEMBL4664489 | 0.82 | ALDH1A1 (0.30) | ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL1228558 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073885-B2 | Vitamin D3 lactone derivatives | TEIJIN PHARMA LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| EP-1589009-B1 | VITAMIN D3 LACTONE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2014-10-08 | — | — | EP | disclosed |
| US-20060148768-A1 | Vitamin d3 lactone derivatives | TEIJIN LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1589009-A1 | VITAMIN D3 LACTONE DERIVATIVE | Teijin Pharma Limited (JP) | 2005-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148768-A1 | Vitamin d3 lactone derivatives | VDR, CYP24A1, CYP2R1 | ALDH1A1 2285/4885TSHR 1346/4885MAPK1 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.